Paul Barr, MD
Enriched profileProfessor of Medicine; Director, Clinical Trials Office, Wilmot Cancer Institute · University of Rochester Medical Center
Paul Barr is Professor of Medicine; Director, Clinical Trials Office, Wilmot Cancer Institute at University of Rochester Medical Center. OpenAlex indexes 837 publications with 23,366 citations (h-index 55); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Paul Barr, MD, is Professor of Medicine at University of Rochester Medical Center / Wilmot Cancer Institute. The public record shows 837 publications with 23,366 citations (h-index 55), centered on Hematology. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 21 companies, 1 NIH-funded awards (2019–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Hematology
- 25 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:
- Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Sponsor: Trustees of Dartmouth College
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Sponsor: Alliance for Clinical Trials in Oncology
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- Janssen Biotech, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.2%Kinase inhibitor61.3%Brukinsa54%Calquence26%Jaypirca20%Part D<11 patientsBCL-2 Inhibitor20.9%Venclexta100%Part D<11 patientsSensory organs
7.1%Corticosteroid7.1%Dexamethasone100%Part D<11 patientsNervous system
5.8%Phenothiazine5.8%Prochlorperazine Maleate100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2019–2026 per NIH RePORTER. The latest:
- Rochester Network Lead Academic Participating Site
University of Rochester
FY2026$1,186,097UG1CA233230 - The Role of Visit Audio Recordings in Triadic Dementia Care
Dartmouth College
FY2026$759,566R01AG077113 - The effect of clinic visit audio recordings for self-management in older adults
Dartmouth College
FY2026$640,587R01AG074959
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
Journal of clinical oncology
Article2026 - Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
American journal of hematology
Letter2025 - Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
American journal of hematology
Letter2025
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/cotainc_paul-barr-md-discusses-current-research-activity-6981607259755716608-nCXn
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
lymphoma.org/researcher-spotlight-paul-barr
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Editorial & leadership roles
journal and society appointments- Member
Lymphoma Committee, Southwest Oncology Group (SWOG)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- Phi Beta Kappa1996verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- John W. Harris
MD Hematology Scholar Award
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- Researcher Spotlight profile
Lymphoma Research Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lymphoma.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Christopher Ritchlin, MD
University of Rochester Medical Center
Karl Kieburtz, MD
University of Rochester Medical Center
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center